Medesis Pharma SA (ALMDP) — Tangible Net Worth Ratio
Medesis Pharma SA (ALMDP) has a Tangible Net Worth Ratio of -99.3% as of June 2022. This metric is calculated by deducting intangible assets (€232.38K) from net assets (€116.62K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See ALMDP current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Medesis Pharma SA Tangible Net Worth Ratio (2021–2021)
This chart shows how Medesis Pharma SA's Tangible Net Worth Ratio has changed across 1 annual periods from 2021 to 2021. As of June 2022, the ratio stands at -99.3%, reflecting net assets of €116.62K with intangible assets of €232.38K EUR. See ALMDP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Medesis Pharma SA (2021–2021)
The table below presents the year-by-year Tangible Net Worth Ratio for Medesis Pharma SA from 2021 to 2021, covering 1 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see ALMDP market cap.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2021 | 84.7% | €1.65 Million | €252.53K | €4.33 Million | — |